Ellen M Ginzler

Ellen M Ginzler

Division of Rheumatology, Department of Medicine, State University of New York Downstate College of Medicine, Brooklyn, NY | State University of New York, Downstate Health ...

KOL Resume for Ellen M Ginzler  (connective tissue disorder, connective tissue disorders, connective, tissue, systemic, disease, disorders, systemic disorders, systemic connective tissue)

Year
2022

Division of Rheumatology, Department of Medicine, State University of New York Downstate College of Medicine, Brooklyn, NY

State University of New York Downstate Medical Center, Brooklyn, New York, USA

2021

State University of New York Downstate Health Sciences University, Brooklyn

Medicine/Rheumatology, SUNY Downstate Medical Center, New York City, New York, USA

2020

Division of Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, USA

SUNY Downstate Medical Center, Brooklyn, New York

2019

SUNY-Downstate Medical Center, Department of Medicine, Brooklyn, NY, USA

State University of New York Downstate College of Medicine, Brooklyn.

SUNY Downstate Medical Center, Brooklyn, New York.

2018

State University of New York Downstate Medical Center, Brooklyn, New York

2017

Downstate Medical Center Rheumatology, Brooklyn, New York, NY, USA

2016

Department of Medicine , SUNY Downstate Medical Center , Brooklyn, New York , USA.

State University of New York Downstate Medical Center, Brooklyn.

2015

SUNY Downstate Medical Center, 450 Clarkson Ave., Brooklyn, NY 11203 USA

2014

Division of Rheumatology, State University of New York Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA

State University of New York Health Science Centre Brooklyn

2013

Division of Clinical Epidemiology, McGill University Health Centre, Montreal, Que., Canada;, Northwestern University Feinberg School of Medicine, Chicago, Ill., USA;, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Que., Canada;, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK;, Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Conn., and, Department of Medicine, University of California, San Francisco, Calif., USA;, Service de Rheumatologie, Toronto Western Hospital, Toronto, Ont., and, Université de Laval, Quebec, Que., Canada;, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA, West Hollywood, Calif., Johns Hopkins University School of Medicine, Baltimore, Md., West Penn Allegheny Health System, Allegheny General Hospital, Pittsburgh, Pa., and, Downstate Medical Center, State University of New York, Brooklyn, N.Y., USA;, University of Calgary, Calgary, Alta, Canada;, University of North Carolina at Chapel Hill, Chapel Hill, N.C., USA;, Division of Rheumatology, University of Montreal Hospital Center, Montreal, Que., and, University of Manitoba, Winnipeg, Man., Canada;, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea;, Department of Rheumatology, Faculty of Medicine, University College London, London, UK;, Rheumatic Diseases Research Unit, Department of Medicine, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain;, Dalhousie University and Capital Health, Halifax, N.S., Canada;, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;, Lund University Hospital, Lund, Sweden;, Hannover Medical School, Medicine, Hannover, Germany;, Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, Calif., USA;, Department of Rheumatology, Rigshospitalet and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark

State University of New York, Downstate Medical Center, 450 Clarkson Avenue, Box 42, Brooklyn, NY 11203, USA

2012

SUNY Downstate Medical Center, 450 Clarkson Avenue, Box 42, Brooklyn, NY 11203, USA

Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, New York;

2011

Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn (E.M.G.)

Vice President and Chairman of MedicineNewark Beth Israel Medical CenterNewark, NJ, USA

2010

SUNY Downstate Medical Center, Brooklyn, New York, NY, USA

2009

Centre for Rheumatology, University College London, London, UK, Department of Nephrology, Columbia University, New York, NY, Division of Nephrology and Hypertension, University of Miami School of Medicine, Miami, FL, Department of Medicine, University of North Carolina, NC, Department of Medicine, State University of New York, Brooklyn, NY, USA, Renal Unit, Addenbrooke's Hospital, Cambridge, UK, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, and Universidad Nacional Autónoma de México, Mexico, Department of Medicine, University of California, San Francisco, CA, USA, Department of Nephrology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China and, Clinical Department, Vifor Pharma Ltd (formerly Aspreva Pharmaceuticals), Victoria, BC, Canada.

Division of Rheumatology, State University of New York, Downstate Medical Center, Brooklyn, New York, USA

2008

Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, New York, USA

State University of New York‐Downstate Medical Center, Brooklyn, NY, and

2007

SUNY-Downstate Medical Center, Brooklyn, NY, USA

Division of Rheumatology, State University of New York-Downstate Medical Center, Brooklyn, New York

2006

Department of Medicine, State University of New York–Downstate Medical Center, Downstate Internal Medicine Associates, Brooklyn, NY, USA

State University of New York–Downstate Medical Center, Brooklyn

2005

From the Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn (E.M.G., C.A.)

State University of New York–Downstate Medical Center, 450 Clarkson Avenue, Box 42, Brooklyn, NY 11203, USA

2004

University of Washington, Seattle, Washington

SUNY Downstate Medical Center, Rheumatology Division, Brooklyn, New York, USA

Georges Pompidou European Hospital, Paris, France

National Institutes of Health, Bethesda, Maryland

Columbia Presbyterian Medical Center, New York, New York

2002

State University of New York Health Science Center, Brooklyn, New York

2001

Downstate Medical Center, State University of New York, 450 Clarkson Avenue, Box 42, 11203, Brooklyn, NY, USA

2000

SUNY Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 42, Brooklyn, NY 11203, USA Lupus

1998

Rheumatology Division, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 42, Brooklyn, NY 11203, USA

1997

Division of Rheumatology, Department of Medicine, Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio

National Institutes of Health, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, Bethesda, Maryland, USA

State University of New York Health Science Center at Brooklyn

1996

Department of Medicine, Graduate Program in Immunology, The Cornell University Medical College, New York 10021, USA.

1992

State University of New York Health Science Center, Brooklyn.

Rheumatic Disease Unit and the Clinical Epidemiology Unit, Wellesley Hospital, University of Toronto, Toronto, Ontario, Canada

1991

State University of New York Health Science Center at Brooklyn, Brooklyn, New York, USA

1988

Downstate Medical Center Brooklyn, NY

Associate Professor of Medicine, Rheumatology Division, Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York

 

Prominent publications by Ellen M Ginzler

KOL Index score: 23603

BACKGROUND: Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults with lupus nephritis, improved complete renal response rates in patients with lupus nephritis in a phase 2 trial. This study aimed to evaluate the efficacy and safety of voclosporin for the treatment of lupus nephritis.

METHODS: This multicentre, double-blind, randomised phase 3 trial was done in 142 hospitals and clinics across 27 countries. Patients with a diagnosis of systemic lupus ...

Known for Lupus Nephritis |  Patients Voclosporin |  3 Trial |  Efficacy Safety |  Primary Endpoint
KOL Index score: 15659

OBJECTIVE: To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo plus standard therapy in active systemic lupus erythematosus (SLE).

METHODS: In a phase III, multicenter, randomized, placebo-controlled trial, 819 antinuclear antibody-positive or anti-double-stranded DNA-positive SLE patients with scores ≥6 on the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLE Disease ...

Known for Phase Iii |  Lupus Erythematosus |  Standard Therapy |  Antinuclear Antibodies |  10 Belimumab
KOL Index score: 15160

OBJECTIVE: The Manhattan Lupus Surveillance Program (MLSP) is a population-based registry designed to determine the prevalence of systemic lupus erythematosus (SLE) in 2007 and the incidence from 2007 to 2009 among residents of New York County (Manhattan), New York, and to characterize cases by race/ethnicity, including Asians and Hispanics, for whom data are lacking.

METHODS: We identified possible SLE cases from hospital records, rheumatologist records, and administrative databases. ...

Known for New York |  Systemic Lupus |  Incidence Prevalence |  Race Ethnicity |  Asians Hispanics
KOL Index score: 13613

BACKGROUND AND AIMS: We studied damage accrual and factors determining development and progression of damage in an international cohort of systemic lupus erythematosus (SLE) patients.

METHODS: The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort recruited patients within 15 months of developing four or more 1997 American College of Rheumatology (ACR) criteria for SLE; the SLICC/ACR damage index (SDI) was measured annually. We assessed relative rates of ...

Known for Inception Cohort |  Damage Accrual |  Systemic Lupus |  International Collaborating |  Sle Slicc
KOL Index score: 13394

OBJECTIVE: To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE).

METHODS: Patients with a Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score >/=4 (n = 449) were randomly assigned to belimumab (1, 4, or 10 mg/kg) or placebo in a 52-week study. ...

Known for Lupus Erythematosus |  Active Systemic |  Antinuclear Antibodies |  Belimumab Patients |  Week Placebo
KOL Index score: 13208

INTRODUCTION: This trial evaluated the safety, biologic activity, and pharmacokinetics of belimumab, a fully human monoclonal antibody that inhibits the biologic activity of the soluble form of the essential B-cell survival factor B-lymphocyte stimulator (BLyS) in patients with systemic lupus erythematosus (SLE).

METHODS: Seventy patients with mild-to-moderate SLE were enrolled in a phase I, double-blind, randomized study and treated with placebo (n = 13) or belimumab (n = 57) at four ...

Known for Biologic Activity |  Monoclonal Antibodies |  Lupus Erythematosus |  Belimumab Placebo |  Sle Patients
KOL Index score: 12998

OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.

METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% ...

Known for C1q Anti |  Lupus Erythematosus |  Renal Involvement |  Patients Sle |  Studies Complement
KOL Index score: 12981

BACKGROUND: Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis.

METHODS: We carried out a 36-month, randomized, double-blind, double-dummy, phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per kilogram of body weight per day), plus placebo in each group, in patients who met response criteria during a 6-month induction trial. ...

Known for Lupus Nephritis |  Maintenance Therapy |  Patients Azathioprine |  Treatment Failure |  Mycophenolate Mofetil
KOL Index score: 12616

BACKGROUND: Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable.

METHODS: We conducted a 24-week randomized, open-label, noninferiority trial comparing oral mycophenolate mofetil (initial dose, 1000 mg per day, increased to 3000 mg per day) with monthly intravenous cyclophosphamide (0.5 g per square meter of body-surface area, increased to 1.0 g per square meter) as ...

Known for Mycophenolate Mofetil |  Intravenous Cyclophosphamide |  Lupus Nephritis |  24 Weeks |  Complete Remission
KOL Index score: 12103

OBJECTIVE: To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n = 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 currently ongoing).

METHODS: Patients (n = 345) who completed a double-blind, placebo-controlled, 52-week study of belimumab 1, 4, or 10 mg/kg and 24-week extension of belimumab (placebo switched to 10 mg/kg; belimumab same dose or switched to 10 mg/kg) could receive belimumab 10 mg/kg in an open-label ...

Known for 7 Years |  Standard Therapy |  Patients Belimumab |  Lupus Erythematosus |  Active Sle
KOL Index score: 11970

OBJECTIVE: To examine the frequency and characteristics of headaches and their association with global disease activity and health-related quality of life (HRQOL) in patients with systemic lupus erythematosus (SLE).

METHODS: A disease inception cohort was assessed annually for headache (5 types) and 18 other neuropsychiatric (NP) events. Global disease activity scores (SLE Disease Activity Index 2000 [SLEDAI-2K]), damage scores (Systemic Lupus International Collaborating Clinics/American ...

Known for Systemic Lupus Erythematosus |  Patients Headache |  Inception Cohort |  Np Events Sle |  Global Disease Activity
KOL Index score: 11923

Allelic variants of Fc gamma R confer distinct phagocytic capacities providing a mechanism for heritable susceptibility to immune complex disease. Human Fc gamma RIIa has two codominantly expressed alleles, R131 and H131, which differ substantially in their ability to ligate human IgG2. The Fc gamma RIIa-H131 is the only human Fc gamma R which recognizes IgG2 efficiently and optimal IgG2 handling occurs only in the homozygous state. Therefore, since immune complex clearance is essential ...

Known for African Americans |  Gamma Riia |  Lupus Nephritis |  Heritable Risk Factors |  Sle Patients
KOL Index score: 11776

INTRODUCTION: Atacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL (a proliferation-inducing ligand) and BLyS (B-lymphocyte stimulator). The APRIL- LN study aimed to evaluate the efficacy and safety of atacicept in patients with active lupus nephritis (LN), receiving newly initiated corticosteroids (CS) and mycophenolate mofetil (MMF).

METHODS: This was a randomized, double-blind, placebo-controlled Phase II/III, 52-week study. At ...

Known for Atacicept Patients |  Lupus Nephritis |  Efficacy Safety |  Serum Immunoglobulin |  4 Weeks
KOL Index score: 11744

OBJECTIVE: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE.

METHODS: The classification criteria were derived from a set of 702 expert-rated patient scenarios. Recursive partitioning was used to derive an ...

Known for Classification Criteria |  Lupus International |  Sle Patient |  Antinuclear Biopsy |  Derivation Validation

 

Ellen M Ginzler: Influence Statistics

Sample of concepts for which Ellen M Ginzler is among the top experts in the world.
Concept World rank
erythematosus older #1
renal criteria #1
epcr represent #1
renal involvement baseline #1
prematurely terminated trial #1
protection higher frequency #1
rapid aggressive therapy #1
nephritis international #1
dose switched #1
179 patients voclosporin #1
1 atacicept #1
voclosporin 178 #1
additional criterion proteinuria #1
erythematosus new #1
antimalarial cardiac toxicity #1
traditional therapies agents #1
sle computer #1
frentizole 500 #1
mycophenolate mofetil baseline #1
calendaryear periods #1
improvement belimumab #1
178 voclosporin #1
renal histopathology findings #1
standard specialized conditions #1
mofetil intravenous #1
voclosporin combination #1
662 patients sle #1
new guidelines decade #1
phytomitogen increasing concentrations #1
sle patients data #1
antiinjury biomarkers #1
sle qpv #1
systemic purines #1
frequency azathioprine #1
frentizole benzothiazoles humans #1
7 prevention #1
selena version #1
3 active disease #1
adiponectin membrane epcr #1
patients qpv #1
lupus nephritis manifestation #1
deficit active protein #1
remission longterm outcomes #1
new guidelines screening #1
azathioprine computers #1
monthly belimumab #1
erythematosus issues #1
active urinary sediment #1
5 leukopenia #1
elevated antidsdna antibodies #1

Key People For Systemic Lupus Erythematosus

Top KOLs in the world
#1
David Alan Isenberg
systemic lupus erythematosus patients sle rheumatoid arthritis
#2
Michelle A Petri
systemic lupus erythematosus lupus nephritis patients sle
#3
D Gladman Gladman
psoriatic arthritis systemic lupus erythematosus patients psa
#4
Murray B Urowitz
systemic lupus erythematosus patients sle lupus nephritis
#5
James F Fries
rheumatoid arthritis physical function systemic lupus erythematosus
#6
Norman Talal
sex hormones lupus erythematosus sjögrens syndrome

Ellen M Ginzler:Expert Impact

Concepts for whichEllen M Ginzlerhas direct influence:Systemic lupus erythematosus,  Lupus erythematosus,  Systemic lupus,  Lupus nephritis,  Mycophenolate mofetil,  Patients sle,  Np events,  Sle patients.

Ellen M Ginzler:KOL impact

Concepts related to the work of other authors for whichfor which Ellen M Ginzler has influence:Systemic lupus erythematosus,  Lupus nephritis,  Sle patients,  Autoimmune diseases,  Mycophenolate mofetil,  Rheumatoid arthritis,  Organ damage.


 

Tools

Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


Division of Rheumatology, Department of Medicine, State University of New York Downstate College of Medicine, Brooklyn, NY | State University of New York, Downstate Health Sciences University, Brooklyn, NY. | State University of New York Downstate Me

download
FREE Custom List